Analyst Price Targets — IMVT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2026 10:35 am | Douglas Tsao | H.C. Wainwright | $40.00 | $35.56 | StreetInsider | Immunovant (IMVT) PT Raised to $40 at H.C. Wainwright |
| January 6, 2026 12:55 pm | — | Wolfe Research | $50.00 | $24.97 | TheFly | Immunovant upgraded to Outperform at Wolfe on improving Graves' perception |
| December 18, 2025 1:29 pm | Yatin Suneja | Guggenheim | $41.00 | $26.27 | TheFly | Immunovant price target lowered to $41 from $44 at Guggenheim |
| October 14, 2025 10:12 am | — | Truist Financial | $16.00 | $17.35 | TheFly | Immunovant initiated with a Hold at Truist |
| September 10, 2024 6:40 am | Douglas Tsao | H.C. Wainwright | $51.00 | $30.20 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT) |
| June 3, 2024 7:22 am | Leland Gershell | Oppenheimer | $46.00 | $25.39 | TheFly | Immunovant price target lowered to $46 from $50 at Oppenheimer |
| May 30, 2024 2:40 pm | Yatin Suneja | Guggenheim | $48.00 | $26.41 | StreetInsider | Immunovant (IMVT) PT Lowered to $48 at Guggenheim |
| May 30, 2024 7:41 am | Yasmeen Rahimi | Piper Sandler | $57.00 | $27.83 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT) |
| March 13, 2024 5:29 am | Corinne Johnson | Goldman Sachs | $50.00 | $31.82 | StreetInsider | Goldman Sachs Starts Immunovant (IMVT) at Buy |
| September 26, 2022 5:29 am | Colin Bristow | UBS | $5.00 | $4.88 | TheFly | Immunovant downgraded to Neutral from Buy at UBS |
Latest News for IMVT
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a…
Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMVT.
U.S. House Trading
No House trades found for IMVT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.